Dr Andreas Makris

Consultant Clinical Oncologist


Clinical Interests

  • Breast cancer

Professional Memberships

  • British Medical Association
  • Royal College of Radiologists
  • British Orthopaedic Association
  • American Society of Clinical Oncology
  • European Society for Medical Oncology


Personal profile

Dr Andreas Makris MA MD FRCP FRCR trained in medicine at Oriel College, Oxford and Sheffield University Medical School.  He completed his oncology training at Weston Park Hospital in Sheffield and the Royal Marsden Hospital in London.

He has been a Consultant Clinical Oncologist at the Mount Vernon Cancer Centre in London since 1997, specialising in the treatment of breast cancer. He is an Honorary Senior Lecturer with University College London and the Institute of Cancer Research.  He has helped to develop breast cancer services at the Mount Vernon Cancer Centre and Network.

Dr Makris has been a clinical expert for NICE (National Institute for Clinical Excellence) in its evaluation of several breast cancer treatments. He has been a member of the NCRI Breast Clinical Studies Group and the Breast Cancer Campaign Scientific Advisory Committee and is also a member of ASCO, RCP, RCR, BACR, BOA and ESMO.

Dr Makris is the Lead of the Mount Vernon Breast Cancer Research Unit where he has established an active breast cancer research programme, with participation in local, national and international trials. His research interests include neoadjuvant therapy, biomarkers of response to treatment, functional imaging and targeted therapies.

Dr Andreas Makris has published more than 100 papers mainly related to breast cancer. He is a member of the trial management committees of several national breast cancer trials. Dr Makris is the holder of several research grants and is a co-Chief investigator of OPTIMA, a UK national trial which has received £2 million funding from the HTA to investigate the role of multiparameter assays in selecting women with hormone-sensitive breast cancer who may not benefit from chemotherapy.

Year qualified: